JP4744782B2 - 癌の治療のための化学療法剤との多糖の同時投与 - Google Patents

癌の治療のための化学療法剤との多糖の同時投与 Download PDF

Info

Publication number
JP4744782B2
JP4744782B2 JP2002574987A JP2002574987A JP4744782B2 JP 4744782 B2 JP4744782 B2 JP 4744782B2 JP 2002574987 A JP2002574987 A JP 2002574987A JP 2002574987 A JP2002574987 A JP 2002574987A JP 4744782 B2 JP4744782 B2 JP 4744782B2
Authority
JP
Japan
Prior art keywords
cancer
galactomannan
therapeutic agent
acid
hydrolyzed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002574987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525143A5 (enExample
JP2004525143A (ja
Inventor
クリオソフ，アナトール
プラット，デイビット
Original Assignee
プロ−ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/818,596 external-priority patent/US6645946B1/en
Application filed by プロ−ファーマシューティカルズ，インク． filed Critical プロ−ファーマシューティカルズ，インク．
Publication of JP2004525143A publication Critical patent/JP2004525143A/ja
Publication of JP2004525143A5 publication Critical patent/JP2004525143A5/ja
Application granted granted Critical
Publication of JP4744782B2 publication Critical patent/JP4744782B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2002574987A 2001-03-27 2002-03-27 癌の治療のための化学療法剤との多糖の同時投与 Expired - Lifetime JP4744782B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/818,596 2001-03-27
US09/818,596 US6645946B1 (en) 2001-03-27 2001-03-27 Delivery of a therapeutic agent in a formulation for reduced toxicity
US31709201P 2001-09-04 2001-09-04
US60/317,092 2001-09-04
PCT/US2002/009524 WO2002076474A1 (en) 2001-03-27 2002-03-27 Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2004525143A JP2004525143A (ja) 2004-08-19
JP2004525143A5 JP2004525143A5 (enExample) 2009-06-25
JP4744782B2 true JP4744782B2 (ja) 2011-08-10

Family

ID=26980760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002574987A Expired - Lifetime JP4744782B2 (ja) 2001-03-27 2002-03-27 癌の治療のための化学療法剤との多糖の同時投与

Country Status (7)

Country Link
US (1) US7012068B2 (enExample)
EP (1) EP1383516B1 (enExample)
JP (1) JP4744782B2 (enExample)
AT (1) ATE532524T1 (enExample)
DK (1) DK1383516T3 (enExample)
ES (1) ES2376739T3 (enExample)
WO (1) WO2002076474A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
JP5021309B2 (ja) * 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
WO2005056022A1 (ja) * 2003-12-12 2005-06-23 Taiyo Kagaku Co., Ltd. 腸疾患改善用組成物
CA2570570A1 (en) * 2004-06-22 2006-01-05 Pro-Pharmaceuticals, Inc. Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
WO2011016811A1 (en) * 2009-08-07 2011-02-10 Pro-Pharmaceuticals, Inc. Methods for reducing the incidence of chemotherapy - induced mucositis
US8604187B2 (en) * 2010-01-14 2013-12-10 North Texas Medical Associates Compositions and methods of aloe polysaccharides
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
CA3102155A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
US5118673A (en) * 1982-05-07 1992-06-02 Carrington Laboratories, Inc. Uses of aloe products
WO1993008810A1 (en) * 1991-11-05 1993-05-13 Carrington Laboratories, Inc. Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure
JP3801658B2 (ja) 1993-03-02 2006-07-26 太陽化学株式会社 β−グルクロニダーゼ活性抑制組成物
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
EP0721784A4 (en) 1994-07-29 1997-09-17 Kanegafuchi Chemical Ind SLOW RELEASE DRUG PREPARATION
US5861142A (en) * 1996-03-25 1999-01-19 Schick; Mary Pichler Method for promoting hair, nail, and skin keratinization
AU7201998A (en) * 1997-05-06 1998-11-27 Zhi Liu Drug delivery system
AU749623B2 (en) 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
KR20000011247A (ko) * 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
WO2000018377A1 (en) 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
WO2000059481A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT

Also Published As

Publication number Publication date
ATE532524T1 (de) 2011-11-15
EP1383516A1 (en) 2004-01-28
EP1383516A4 (en) 2007-08-01
DK1383516T3 (da) 2012-02-20
US7012068B2 (en) 2006-03-14
US20030064957A1 (en) 2003-04-03
WO2002076474A1 (en) 2002-10-03
ES2376739T3 (es) 2012-03-16
EP1383516B1 (en) 2011-11-09
JP2004525143A (ja) 2004-08-19

Similar Documents

Publication Publication Date Title
US7893252B2 (en) Selectively depolymerized galactomannan polysaccharide
EP2303328B1 (en) Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy
AU2002311985B2 (en) Methods for inhibiting angiogenesis
US7012068B2 (en) Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
CN113365613A (zh) 透明质酸和表没食子儿茶素-3-o-没食子酸酯的缀合物和纳米颗粒及其用途
CN101507730A (zh) 表没食子儿茶素没食子酸酯与柔红霉素的组合物及其应用
JP2018513130A (ja) Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用
JPS61151123A (ja) 安定化された３―オキシゲルミルプロピオン酸ポリマーを有効成分とする免疫調整剤
US6645946B1 (en) Delivery of a therapeutic agent in a formulation for reduced toxicity
US6914055B2 (en) Delivery of a therapeutic agent in a formulation for reduced toxicity
US6982255B2 (en) Delivery of a therapeutic agent in a formulation for reduced toxicity
KR20200116394A (ko) CP2c 표적 펩티드 기반 항암제
KR102187681B1 (ko) 히알루론산 나노입자를 함유하는 섬유증의 예방 또는 치료용 약학 조성물
US20040048808A1 (en) Methods for inhibiting angiogenesis
Eward et al. Novel niclosamide stearate prodrug therapeutic shows potential efficacy against naturally occurring canine osteosarcoma in a clinical feasibility study
KR102063398B1 (ko) Pfi-3를 포함하는 신장암의 예방 또는 치료용 조성물
US10758581B2 (en) Treatment of cancer
KR20160045072A (ko) 혈액학적 신생물의 치료를 위한 하이드록시알킬 전분
US20040006138A1 (en) Pharmaceutical composition useful for treating chronic myeloid leukemia
JPH01275531A (ja) 癌細胞転移抑制剤
CN109846876A (zh) 木脂素类化合物在抗肿瘤中的应用及其药物制备
TW201247208A (en) A pharmaceutical composition for inhibiting the recurrence, progression or metastasis of liver cancer
JPH07309758A (ja) 癌細胞転移阻害剤
HUT73378A (en) Biologically active agent having immunomodulating properties, method for its obtaining and pharmaceutical preparation based on it
NZ619380B2 (en) Combined pharmaceutical compositions for the treatment of tumours

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090311

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090428

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101001

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110511

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140520

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4744782

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term